[Expression and significance of p53-related proteins and LMP-1 in nasal NK/T-cell lymphoma].
OBJECTIVE
To investigate the expression of murine double minute 2 (mdm2), p53, p21 and latent membrane protein 1 (LMP-1) in nasal NK/T-cell lymphoma (NKTL) and analyze their relationship with the clinical stage and prognosis.


METHODS
The clinicopathological and follow-up data of 62 patients with NKTL proven by pathology were collected. Paraffin-embedded tissue sections were examined for mdm2, p53, p21 and LMP-1 proteins by tissue microarray technique and immunohistochemistry. In situ hybridization was used to detect EBER1/2.


RESULTS
The positive expression rates of mdm2, p53, p21 and LMP-1 proteins in NKTL were 61.3%, 79.0%, 58.1% and 48.4%, respectively, and EBER1/2 was 90.3%. The positive expression rates of mdm2 in Ann Arbor stage I, II, III and IV NKTL were 43.5%, 62.5%, 73.3% and 87.5%, respectively; p53 were 69.6%, 75.0%, 86.7% and 100.0%; p21 were 47.8%, 56.3%, 60.0% and 87.5%; while those of LMP-1 were 60.9%, 50.0%, 26.7% and 50.0%, respectively. With the progression of tumor, the positive expression rates of mdm2, p53 and p21 proteins gradually increased. There were statistically significant differences between them (P<0.05). There were statistically positive correlations among those three genes (P<0.05). The prognosis of the positive expression group of these three genes was worse than that of negative expression group (P<0.05). No statistically significant difference was observed between the expression of LMP-1 protein and the clinical stage or prognosis (P>0.05). The expression of p53 protein was an independent prognostic factor.


CONCLUSIONS
The expression of mdm2, p53 and p21 proteins is closely related with the pathogenesis and progression of NKTL. They are good markers for judgement of the biological behavior of NKTL. The expression of p53 protein is an independent prognostic factor. Though no significant relationship was found between the expression of LMP-1 protein and the clinical stage or prognosis, it may play some role in tumor progression.
Department of Otolaryngology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu 610072, China. xugoto@yahoo.com.cn
Gang
G
Xu
Huai-fu
HF
Wang
Gang
G
He
Ke
K
Xie
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D011241:Prednisone / Q000627:therapeutic use; D051736:Proto-Oncogene Proteins c-mdm2 / Q000378:metabolism; D012367:RNA, Viral / Q000378:metabolism; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D014750:Vincristine / Q000627:therapeutic use; D014763:Viral Matrix Proteins / Q000378:metabolism*; D055815:Young Adult
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; C037662:EBV-associated membrane antigen, Epstein-Barr virus; C099537:Epstein-Barr virus encoded RNA 1; D012367:RNA, Viral; D016159:Tumor Suppressor Protein p53; D014763:Viral Matrix Proteins; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D051736:Proto-Oncogene Proteins c-mdm2; D011241:Prednisone